旧的西方投资管理公司将Apellis制药公司的股份增加11%,现在拥有价值360万美元的股票。 Old West Investment Management boosts Apellis Pharmaceuticals holdings by 11%, now owning $3.6 million worth of stock.

旧的西方投资管理有限公司在Apellis制药公司持有的股份增加了11%,根据证交会的文件,在Q4购买了11 220股股份。 Old West Investment Management LLC increased its holdings in Apellis Pharmaceuticals by 11%, buying 11,220 shares in Q4, according to its SEC filing. 该基金现在拥有113 623个股份,价值约360万美元,占其投资组合的1.5%。 The fund now owns 113,623 shares, worth about $3.6 million, making up 1.5% of its portfolio. Apellis是一家以自发免疫和炎症为重点的生物制药公司,其库存受到分析师的“最佳购买”评级,目标价格为45.59美元。 Apellis, a biopharmaceutical company focused on autoimmune and inflammatory diseases, has seen its stock receive a "Moderate Buy" rating with a target price of $45.59 from analysts.